Coupling Brain-Tumor Biophysical Models and Diffeomorphic Image
  Registration by Scheufele, Klaudius et al.
Coupling Brain-Tumor Biophysical Models and Diffeomorphic Image
Registration
Klaudius Scheufelea, Andreas Mangb, Amir Gholamid, Christos Davatzikose,
George Birosc, Miriam Mehl1a
aUniversity of Stuttgart, IPVS, Universita¨tstraße 38, 70569 Stuttgart, Germany
bUniversity of Houston, Department of Mathematics, 3551 Cullen Blvd., Houston, Texas 77204-3008, USA
cUniversity of Texas, ICES, 201 East 24th St, Austin, Texas 78712-1229, USA
dUniversity of California Berkeley, EECS, Berkeley, CA 94720-1776, USA
eDepartment of Radiology, University of Pennsylvania School of Medicine, 3700 Hamilton Walk, Philadelphia, PA 19104, USA
Abstract
We present the SIBIA (Scalable Integrated Biophysics-based Image Analysis) framework for joint image
registration and biophysical inversion and we apply it to analyse MR images of glioblastomas (primary
brain tumors). Given the segmentation of a normal brain MRI and the segmentation of a cancer patient
MRI, we wish to determine tumor growth parameters and a registration map so that if we “grow a tu-
mor” (using our tumor model) in the normal segmented image and then register it to the segmented
patient image, then the registration mismatch is as small as possible. We call this “the coupled problem”
because it two-way couples the biophysical inversion and registration problems. In the image registra-
tion step we solve a large-deformation diffeomorphic registration problem parameterized by an Eulerian
velocity field. In the biophysical inversion step we estimate parameters in a reaction-diffusion tumor
growth model that is formulated as a partial differential equation (PDE). In SIBIA, we couple these two
steps in an iterative manner. We first presented the components of SIBIA in “Gholami et al, Framework for
Scalable Biophysics-based Image Analysis, IEEE/ACM Proceedings of the SC2017”, in which we derived paral-
lel distributed memory algorithms and software modules for the decoupled registration and biophysical
inverse problems. In this paper, our contributions are the introduction of a PDE-constrained optimization
formulation of the coupled problem, the derivation of the optimality conditions, and the derivation of a
Picard iterative scheme for the solution of the coupled problem. In addition, we perform several tests to
experimentally assess the performance of our method on synthetic and clinical datasets. We demonstrate
the convergence of the SIBIA optimization solver in different usage scenarios. We demonstrate that us-
ing SIBIA, we can accurately solve the coupled problem in three dimensions (2563 resolution) in a few
minutes using 11 dual-x86 nodes.
Keywords: biophysically constrained diffeomorphic image registration, tumor growth, atlas registration,
adjoint-based methods, parallel algorithms
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1. Introduction
We present the SIBIA framework that comprises a mathematical formulation, algorithms, and software
for joint image registration and biophysical inversion. Given a volumetric segmentation of a magnetic res-
onance imaging (MRI) dataset of a glioma (primary brain tumor) patient, SIBIA simultaneously registers
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Figure 1: Here we summarize the joint registration and biophysical inversion in SIBIA. (a) shows the segmented healthy brain (the atlas), (b)
tumor-bearing atlas brain generated by biophysical simulation, (c) patient tumor registered to atlas (in atlas space), (d) tumor-bearing patient
brain. The inputs are images (a) and (d). The outputs are the tumor growth parameters, the registration parameters, and images (b) and (c).
In SIBIA, we compute tumor-growth and registration parameters so that images (b) and (c) are as similar as possible. In this example, the
biophysical tumor growth parameters are the initial conditions for a reaction-diffusion equation. The registration is parameterized using an
Eulerian framework and a velocity field that is used to advect image (d) to image (c).
this image to a segmented MRI dataset of a normal brain (an atlas) and fits a biophysical tumor growth
model. Such a joint registration-biophysical inversion approach is motivated by two practical problems:
(1) Often, we need to calibrate complex macroscopic biophysical PDE models using a single-time snap-
shot dataset. Since the biophysical model is typically a dynamical system, it is unclear how to fit model
parameters using just a single-time dataset since we don’t have the initial state. Replacing the missing
second patient snapshot by a healthy atlas and coupling registration between patient and atlas with the
tumor growth model attempts to resolve this problem. (2) We want to register normal MR images to MR
images with abnormalities. This normal-to-abnormal registration finds applications in surgical planning
(e.g., mapping structural and functional information to a patient image), longitudinal studies, followups,
or population studies.
We focus on applying SIBIA to the registration of segmented normal images to segmented MR im-
ages of glioma patients. Many image analysis workflows for gliomas involve fitting biophysical models
for tumor characterization and prognosis (Swanson et al., 2008; Rahman et al., 2017), for image registra-
tion (Mohamed et al., 2006; Kwon et al., 2014a; Zacharaki et al., 2009), and for image segmentation (Bakas
et al., 2015; Gooya et al., 2013; Prastawa et al., 2009). In many methods for these image analysis and
biophysical modeling problems, an essential step is the solution of an inverse tumor-growth problem, i.e.,
for instance the calculation of the initial conditions for tumor growth; this process can be combined with
registration and segmentation as in (Gooya et al., 2013).
1.1. Statement of the problem and summary of the approach
The specific scenario we are interested in is summarized in Fig. 1. We are given a single snapshot of
the multi-modal MRI of a glioma patient. Let us assume that we have obtained a segmentation of the MRI
in healthy tissue and abnormal tissue, i.e., we have labels for white matter, gray matter, cerebrospinal fluid
(CSF), cerebellum, ventricles, and tumor 3. Since the tumor-growth problem is typically a time dependent
problem, we need at least two time snapshots to invert for parameters, ideally we would like to have a
pre-cancer image of the healthy brain of the patient, the white, gray, and CSF structure, which we don’t
have, though. The basic idea to tackle this issue is to use a pre-segmented normal healthy brain (atlas) as
a means to create a second snapshot. This is the step that requires registration. The best way to describe
this is to consider the “forward problem”: Assume we are given the (haelthy) atlas, a tumor-growth model,
and a deformation map (represented as advection with a given velocity field). Then, we first apply the
tumor growth model to the healthy image and produce a new segmentation that has both healthy tissue
3In reality, the tumor has subclasses like edema, necrotic tumor, enhancing tumor, and others. Since we’re using a very simple
tumor model, we don’t consider these subclases here.
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and tumor. In a second step, we warp this image using the given deformation map. This image is the
tumor-plus-deformation warped atlas. In the “inverse problem”, we seek to compute the tumor-growth
parameters and deformation parameters so that the tumor-plus-deformation warped atlas image matches
the patient image.
Thus, SIBIA combines the following steps: (i) a forward tumor solver growing a virtual (or synthetic)
tumor in the segmented healthy atlas brain, (ii) the inverse tumor solver determining the initial condition
for tumor growth given an observation at a later time, (iii) a forward linear advection solver that implicitly
computes the warped image given the velocity field, and (iv) a large-deformation diffeomorphic image
registration solver. Both inversion and registration are optimization problems.
1.2. Contributions
(i) We formulate a coupled tumor growth and registration optimization problem in §3 and derive its
gradient.
(ii) We derive the first order optimality conditions for the joint registration and biophysical inversion for
brain tumor growth.
(iii) Instead of using a gradient descent method, we propose a Picard iteration scheme for solving the
system based on modular tumor and image registration components, a generic idea that can be
extended to other problems.
(iv) We conduct numerical experiments on synthetic and real data that demonstrate the validity and
efficiency of our approach, in particular we show that the Picard iteration reduces the gradient and
converges to a local minimum.
(v) We examine the sensitivity of our solver on the choice of the tumor model variant. We consider three
variants of the tumor model: a reaction model, a reaction-diffusion model, and a simple radial basis
approximation (no time evolution; the tumor is simply approximated at the observation time). All
these variants can be used depending on the goal of the analysis.
1.3. Limitations and Open Issues
Several limitations and unresolved issues remain. The main limitation is that we don’t have a theoret-
ical proof that the Picard scheme converges4 , we only provide empirical evidence. A second limitation is
that our tumor model does not include mass-effect, we use a simple phenomenological reaction-diffusion
model (Swanson et al., 2000, 2002; Murray, 1989). This model, although it has been proven to be quan-
titatively useful for image analysis and tumor characterization (Mang et al., 2012; Swanson et al., 2008;
Jackson et al., 2015; Lima et al., 2016), has limited predictive capabilities. Its predictive capabilities are
very limited. We are currently working on integrating a mass-effect, which is considered critical for char-
acterizing tumor aggressiveness (Kyriacou et al., 1999; Yankeelov et al., 2013; Mohamed et al., 2006) as
well as richer reaction-diffusion models. SIBIA can naturally be extended to these more complex models
although of course more tests will be necessary to demonstrate convergence of the Picard scheme.
1.4. Literature review
We presented fast algorithms for the individual components of SIBIA in (Gholami et al., 2017) were
we introduced the key computational kernels (reaction-diffusion, advection, and inverse solution based
on FFT and particle-in-mesh methods) and demonstrated their scalability on very large images and
distributed-memory architectures. Our problem formulation results in a mixed-type PDE-constrained
optimization problem that poses significant numerical challenges. We refer to (Biegler et al., 2003; Borzı`
4The optimization problem we’re solving is highly non-convex, so multiple solutions may exist. Our solver convergences to a
local minimum.
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and Schulz, 2012; Herzog and Kunisch, 2010; Hinze et al., 2009) for a general introduction into PDE-
constrained optimization and to (Angelini et al., 2007; Bauer et al., 2013; Mang et al., 2017) for reviews on
its application to medical image analysis. We will limit ourselves to the work most closely related to ours
in the following.
The first component of SIBIA is image registration. We refer to (Modersitzki, 2004; Sotiras et al., 2013)
for a general overview of medical image registration. Registering the atlas to the patient requires finding
correspondences between two topologically different images—one with tumor and one without tumor.
The key issue here is the ill-defined correspondence arising from the presence of a tumor in only one
of the images to be registered. A simple strategy to deal with this issue is to consider the tumor area
as non-informative and mask it from the optimization (Henn et al., 2004; Stefanescu et al., 2004; Brett
et al., 2001) or to relax the registration in the area affected by the tumor (Parisot et al., 2014). This,
however, yields poor registration quality for tumors with severe tissue deformation due to mass effect.
Another strategy is to simultaneously invert for the deformation map and a drift in intensity representing
the imaging abnormality associated with the tumor (Li, 2010; Li et al., 2012), which can also be applied
to other registration problems with topological differences (for instance, pre- and postoperative image
registration (Kwon et al., 2014a)). While it may produce acceptable results for the purpose of atlas-based
segmentation and registration, it can not be used in the context of model prediction—which is our ultimate
goal. Our prior work on diffeomorphic image registration (Mang and Biros, 2015, 2016; Mang et al., 2016;
Mang and Ruthotto, 2017; Mang and Biros, 2017) forms the basis for the proposed methodology based
on the pioneering work in (Christensen et al., 1996; Trouve´, 1998; Beg et al., 2005) (see (Mang and Biros,
2015) for additional references).
The second component of SIBIA is the calibration of brain tumor models to medical imaging data (Gho-
lami et al., 2016b; Gholami, 2017; Gholami et al., 2017; Yankeelov et al., 2013; Miga et al., 1998). The
associated PDE operator is a parabolic, non-linear, reaction-diffusion equation (Murray, 1989; Swanson
et al., 2002). Despite its phenomenological character, this model is capable of generating simulations that
are in good agreement with observations of abnormalities in standard MR imaging data and has been
used by other groups besides ours (Clatz et al., 2005; Hogea et al., 2007; Harpold et al., 2007; Konukoglu
et al., 2010b,a; Le et al., 2016; Lima et al., 2016; Mosayebi et al., 2012; Menze et al., 2011; Mang et al.,
2012; Swanson et al., 2008). Our implementation features inversion operators for the initial tumor con-
centration, for diffusivity parameters, or for the growth rate (Gholami et al., 2016b). Related optimal
control formulations can, e.g., be found in (Colin et al., 2014; Hogea et al., 2008b; Knopoff et al., 2013,
2017; Liu et al., 2014; Mang et al., 2012; Quiroga et al., 2015, 2016; Wong et al., 2015). Unlike most existing
approaches (with the exception of (Kwon et al., 2014b)), our parameterization of the problem (Gholami
et al., 2016b; Gholami, 2017) allows us to invert for multifocal tumors. Numerical methods for solving the
tumor calibration problem are based either on point estimate or Bayesian inference methods (Lima et al.,
2016, 2017). Bayesian inference characterizes the uncertainty in the model parameters. In this paper, we
just focus on methods for point estimates using an adjoint formulation. Our approach can be extended to
the Bayesian setting (Flath et al., 2011).
The integration of biophysical brain tumor simulations with deformable image registration is not
new (Gooya et al., 2013; Hogea et al., 2008a; Mohamed et al., 2006; Zacharaki et al., 2008b,a, 2009). In (Mo-
hamed et al., 2006; Zacharaki et al., 2008b,a, 2009), a purely mechanical model for tumor progression was
used. The two key limitations of the work in (Mohamed et al., 2006; Zacharaki et al., 2008b,a, 2009) are
(i) that the model is oversimplified; it did not provide the capabilities to generate tumors with complex
shapes (ii) that these models do not provide information about the progression and infiltration of cancer-
ous cells into surrounding healthy tissue.The proposed formulation does not share these limitations. The
work that is closest to ours is (Bakas et al., 2015; Kwon et al., 2014a; Hogea et al., 2008a; Gooya et al., 2013).
Here, the authors present a framework for joint segmentation, registration, and tumor modelling. Like-
wise to ours, their approach is based on a PDE constrained optimization problem, where the constraint is
a non-linear, mixed-type reaction-diffusion-advection equation for the tumor cell density.
What sets our work apart are (i) the solver (we do not iterate on both control variables simultaneously;
we perform a block elimination and iterate resulting in an interleaved optimization on the controls using
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globalized Newton–Krylov solvers as opposed to derivative free-optimization (Gooya et al., 2013; Hogea
et al., 2008a; Mohamed et al., 2006; Zacharaki et al., 2008b,a, 2009; Wong et al., 2015)); (ii) an efficient
parallel implementation (Mang et al., 2016; Gholami et al., 2017); (iii) the derivation of the optimality sys-
tems for the fully coupled problem; (iv) the parameterization for the initial condition of the tumor, which
not only allows us to represent multifocal tumors but also to significantly simplify the PDE constraint
without loosing segmentation accuracy; (v) and finally the integration with a state-of-the-art algorithm
for constrained large deformation diffeomorphic image registration (Mang and Biros, 2015, 2016; Mang
et al., 2016; Mang and Biros, 2017).
1.5. Outline
We present the proposed formulation for biophysically constrained diffeomorphic image registraiton
in §3. We show that the optimality systems of our problem are complex, space-time, multi-physics op-
erators that pose significant numerical challenges. We further motivate and explain our choices for the
forward operators for the tumor model and the registration in §3.1 and §3.2 and present the associated in-
version operators. In §4, we discuss the algorithmic details. We summarize the setup for the experiments
in §5.1 and present numerical results on real and synthetic data in §5 and conclude with §6. Additional
material is provided in §Appendix A.
2. Notation
Before presenting the models used for tumor growth and image registration, we summarize the nota-
tion used throughout the manuscript.
Segmentation labels and probability maps. For each healthy brain tissue type, i.e., gray matter (GM), white
matter (WM), and cerebrospinal fluid (CSF; which includes the ventricles), we use a separate probability
map. We represent these probability maps as a space-time vector field
m(x, t) = (mi(x, t))i=1,...,3 ∈ R3 with m1 = mGM, m2 = mWM, m3 = mCSF (1)
with mi(x, t) ∈ [0, 1] defined on the space-time interval Ω × [0, 1]3 with boundary ∂Ω. The domain
occupied by brain tissue (healthy or unhealthy) is denoted by ΩB ⊂ Ω. The fourth probability map is
c(x, t) ∈ [0; 1], also defined in ΩB; c is the output of the tumor forward simulation and represents the
probability to encounter cancerous cells at a location x at time t. For convenience, we also define the
space-time domains U = Ω× (0, 1] and U¯ = Ω× [0, 1).
Labels, i.e., characteristic functions calculated based on given threshold values for tumor and healthy
tissue types are used only in the evaluation of our results to compute Dice coefficients.
Patient and atlas data. Data of the actual patient image are marked with a subscript T (template, mT , cT),
data of patient images advected to the atlas domain with a subscript P (mP, cP), and those of the atlas
brain with a subscript A (mA, cA).
Dependency on time and space. In most formulations, we do not explicitly include the dependency on the
spatial position x, but only the time dependency. For instance, cA(0) denotes the initial tumor probability
map defined in the atlas image, whereas cA(1) is the tumor at time t = 1 (solution of the tumor forward
problem). This is the point in time associated with the patient image. Probability maps in the atlas image
evolve in the non-dimensional (tumor growth) time interval [0, 1]. For diffeomorphic image registration,
we introduce a pseudo-time variable t ∈ [0, 1] and invert for a stationary velocity field v(x); t does not
have a physical meaning; we associate t = 0 with the undeformed patient image (image to be registered;
template image) and t = 1 with its deformed representation. We make more explicit definitions below.
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Vector notation. Given a vector field m ∈ R3, we compute ∇m = (∂jmi)i,j=1,2,3,∈ R3,3. That is, given a
velocity field v ∈ R3, ∇m v ∈ R3 indicates a matrix-vector multiplication. The standard scalar product in
R3 is denoted by “·” and the outer product between two vector fields will be denoted by “⊗”. In addition,
we define the following inner products:
〈m, m˜〉L2(Ω)3 B
3
∑
i=1
〈mi, m˜i〉L2(Ω), ‖m‖2L2(Ω)3 B
3
∑
i=1
‖mi‖2L2(Ω). (2)
3. Formulation
We propose a new coupled formulation based on diffeomorphic image registration and inverse tumor
growth simulation. As an input, we take the tumor-free atlas brain geometry mA(x, 0) (reference image,
healthy atlas) and the tumor-bearing patient geometry mT(x) (template image, patient with tumor) plus
the patient’s tumor probability map cT(x) (template tumor). Our formulation is based on optimal control
theory and results in a coupled PDE-constrained optimization problem. We invert for a stationary velocity
field v(x) := (v1(x), v2(x), v3(x))T (establishes the spatial correspondence between the patient and atlas
image), a parameter vector p (parametrizes the simulated tumor in the tumor-free atlas image), and a
mass-source map w(x) (controls the computed deformation pattern) as follows:
min
v,p,w
J (v, p, w) with J (v, p, w) := Dc(cA, cP) +Dm(mA, mP) + βpSp + βvSv + βwSw (3a)
subject to
∂tcA − div k∇cA − f (cA) = 0 in U, (3b)
cA(0) = Φp in Ω, (3c)
∂tmP +∇mP v = 0 in U, (3d)
mP(0) = mT in Ω, (3e)
∂tcP +∇cP · v = 0 in U, (3f)
cP(0) = cT in Ω, (3g)
div v = w in U (3h)
mA(1) = mA(0)(1− cA(1)) in Ω (3i)
with periodic boundary conditions on ∂Ω. The objective functional J in (3b) consists of the following
building blocks:
(i) the two driving L2-distance measures
Dc(cA, cP) := 12‖cA(1)− cP(1)‖
2
L2(Ω), and Dm(mA, mP) :=
1
2
‖mA(1)−mP(1)‖2L2(Ω)3
that measure the discrepancy between the simulated tumor in atlas space cA(1) (solution of the
tumor forward problem (3b) with initial condition (3c) parametrized by p) and the transported
probability map cP(1) of cancerous cells for the patient data (solution of the registration forward
problem (3f) with initial condition (3g)) and the discrepancy between the healthy tissue probability
maps in atlas space with tumor (calculated according to (3i)) and the transported probability maps
of healthy tissue for the patient data (solution of the registration forward problem (3d) with initial
condition (3e));
(ii) three regularization operators balanced against the discrepancy measures Dc and Dm based on reg-
ularization weights β j > 0, j ∈ {v, w, p} involving
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(a) a regularization operator Sp for Φp (an L2-norm; defined in (7) in §3.1),
(b) a regularization operator Sv for v (an H1 Sobolev norm; defined in (13b) in §3.2), and
(c) a regularization operator Sw for w (an H1 Sobolev norm; defined in (13b) in §3.2).
The remaining parameters are defined as follows: k : ΩB → R3×3 is a diffusion tensor field parametri-
zed by scalar weights that specify the diffusivity in WM and GM (see (Gholami et al., 2016b) for details)
and ρ > 0 is the growth parameter for the logistic growth function f (cA) := ρcA(1− cA) in (3b). Both k
and ρ have different values in gray matter and white matter and vanish everywhere else. Although our
implementation is general, in all our experiments k is just an isotropic diagonal tensor (a scalar function
times the identity tensor). The image registration velocity v is used to transport both the brain geometry
mT and the tumor concentration cT from patient to atlas space. (3i) defines the model for the effect of
tumor growth on the brain geometry mA(0) in the atlas space. We solve this coupled inverse problem with
gradient-based optimization. We use the method of Lagrange multipliers to transform the constrained
problem (3) into an unconstrained one. The Lagrangian of (3) reads
LG (cA, cP, mP, mA(1), α,λc,λm, ν, ξ, p, v, w) = J (p, v, w)
+ 〈α(0), (cA(0)−Φp)〉L2(Ω) +
∫ 1
0
〈α, ∂tcA −∇ · (k∇cA)− f (cA)〉L2(Ω) dt
+
∫ 1
0
〈λm, ∂tmP +∇mP v〉L2(Ω)3 dt + 〈λm(0), mP(0)−mT〉L2(Ω)3
+
∫ 1
0
〈λc, ∂tcP +∇cP · v〉L2(Ω) dt + 〈λc(0), cP(0)− cT〉L2(Ω)
+
∫ 1
0
〈ν, div v− w〉L2(Ω) dt + 〈ξ, mA(1)− (1− cA(1))mA(0)〉L2(Ω)3 ,
(4)
with the state fields cA, cP, mP, and mA(1), the adjoint fields α,λc,λm, ν, and ξ, and the inversion fields
p, v, and w. The strong form of the first-order optimality conditions for Equation 4 is given by the
following equations:
tumor forward δαLG = 0 : given by (3b) and (3c) (5a)
tumor adjoint δcALG = 0 : −∂tα−∇ · k∇α− αρ+ 2αρcA = 0 in U¯, (5b)
δcA(1)LT = 0 : cP(1)− cA(1)− ξmA(0)− α(1) = 0 in Ω. (5c)
registration forward δλLG = 0 : given by (3d) – (3h) (5d)
registration adjoint δmPLG = 0 : −∂tλm − div (λm ⊗ v) = 0 in U¯, (5e)
δmP(1)LG = 0 : mA(1)−mP(1)− λm(1) = 0 in Ω, (5f)
δcPLG = 0 : −∂tλc − div (λcv) = 0 in U¯, (5g)
δcP(1)LG = 0 : cA(1)− cP(1)− λc(1) = 0 in Ω, (5h)
adjoint coupling δmA(1)LG = 0 : mP(1)−mA(1)− ξ = 0 in Ω. (5i)
tumor inversion δpLG = 0 : ∇pSp(p)−ΦTα(0) = 0 in Ω. (5j)
registration inversion δvLG = 0 : ∇vSv(v) +K[
∫ 1
0
(∇mP)Tλm +∇cPλc dt] = 0. (5k)
Note, that (∇m)Tλ = ∑3i λi(∂1mi, ∂2mi, ∂3mi)T and that we haven’t given an equation for w. The operatorK in (5k) is a pseudo-differential operator that is derived by eliminating w in (3h). We discuss it further
in §3.2. In summary, the first-order optimality conditions (5) comprise a system of non-linear partial
differential equations, which is quite formidable since it has 11 fields in addition to the tumor initial
7
condition parameters p. Given mT , cT , mA(0), and k and ρ (in that atlas space at t = 0), we need to solve
the first-order optimality PDEs for the state, adjoint, and inversion variables.
We use an elimination method (or also called a “reduced-space method” (Nocedal and Wright, 2006; Borzı`
and Schulz, 2012)) to solve these equations. That is, we assume that the state and adjoint equations are
fulfilled exactly and require vanishing variations of the Lagrangian with respect to the inversion variables
v, w, and p for an admissible solution of our problem. In our algorithm, we iterate only on p and v as we
eliminate w. Given p and v, we wish to compute the gradient of J , i.e., gp and gv used to update p and
v, respectively. The gradient computation involves the following steps:
1. Solve the forward tumor growth and registration equations (3c)–(3i) for the state variables cA(t),
cP(t), mP(t), mA(1).
2. Compute the coupling adjoint variable ξ from equation (5i).
3. Solve the adjoint tumor equations (5b) and (5c) for α(t).
4. Solve the adjoint registration equations (5e)–(5h) for λm(t) and λc(t).
5. Evaluate the gradients using the inversion equations (5j) and (5k) at v and p:
gv = βv∇vSv(v) +K[
∫ 1
0
(∇mP)Tλm +∇cP λc dt], gp = βp∇pSp(p)−ΦTα(0). (6)
At a stationary point g = (gv, gp)
T vanishes. In §3.1 and §3.2, we present more details for the tumor
forward problem (3b), (3c) and the registration forward problems (3d), (3f), (3e), (3g), respectively. In
addition, we formulate separate inverse problems for tumor growth and image registration that are used
as high-level components in our coupling algorithm presented in 4.1. The latter is based on a Picard
iteration using tumor and registration as modular components instead of a gradient descent or Newton
method with line search for the coupled problem (3).
3.1. The Tumor Model
Forward Tumor Problem. We model the tumor growth based on the population density cA(x, t).
Two main phenomena are included: proliferation of cancerous cells and the net migration of cancer-
ous cells into surrounding healthy tissue (Murray, 1989)5. The proliferation model is a logistic growth
function f (cA) := ρ cA(1− cA) with reaction coefficient ρ(x) := ρ f ρ0(x). ρ f denotes the scaling of the
spatially variable characteristic growth rate parameters defined by white and gray matter, i.e., ρ0(x) :=
ρw mWM(x) + ρg mGM(x). The migration model is based on an inhomogeneous (potentially anisotropic)
diffusion process with diffusion coefficient k(x) := k f k0(x)I + ka T(x). Here, k f and ka are the scaling
factors for the isotropic and anisotropic parts of the diffusion tensor, T(x) is a weighted diffusion tensor
modelling anisotropy. In our test cases in §5, we always use isotropic diffusion, i.e., ka = 0. The isotropic
part is k0(x) := kwmWM(x) + kgmGM(x). This yields a non-linear parabolic PDE with non-constant coeffi-
cients for the tumor concentration c given by
∂t cA − div k∇cA − f (cA) = 0 in ΩB × (0, 1], (7a)
∂ncA = 0 on ∂ΩB × (0, 1], (7b)
cA(0) = Φp in ΩB. (7c)
We use a parametrizationΦp for the tumor initial condition cA(0) as originally in (7c) in an np-dimensional
space spanned by a Gaussian basis functions, i.e., p ∈ Rnp , Φp := ∑npi=1 Φi pi with Gaussian basis functions
Φi : ΩB → R. We set the Gaussians in CSF to zero to prevent a spurious diffusion of cancerous cells into
the area associated with CSF.
5Displacement of healthy tissue as a result of tumor growth (mass effect) is currently neglected in our model.
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For notational convenience, we represent the process of solving (7) with the operator
T fwd(p) := cA(1) (8)
mapping the parametrization p of the initial conditions in (7c) to the tumor density cA(1) at time t = 1.
This simple model is by no means predictive on its own, but is the de-facto standard approach when
it comes to modeling tumor progression as seen in medical imaging (Swanson et al., 2000, 2008; Clatz
et al., 2005; Harpold et al., 2007; Konukoglu et al., 2010b; Hogea et al., 2008a). Some results available
in the literature have suggested that this model can offer (to some extent) predictive capabilities when
integrated with medical imaging information (Swanson et al., 2000; Tomer et al., 2014). Its usefulness is
in segmentation and registration algorithms that use normal atlas information and in producing features
(e.g., tumor parameters) to augment image-based features for tumor staging and prognosis. Note that un-
like §3, we have stated the tumor problem in ΩB with Neumann boundary conditions (7b), which is the
actual biophysical problem. In our numerical implementation, however, we extend k by a small parame-
ter, set ρ = 0 in Ω \ΩB, discretize in Ω using periodic boundary conditions and use a penalty approach
to approximate the boundary conditions at ∂ΩB. One can show that this ‘’fictitious domain method‘’
approximates (7) and as we refine the discretization it converges to the correct solution (compare (Hogea
et al., 2008a; Gholami et al., 2016b)).
Inverse Tumor Problem. In the inverse tumor problem, we seek an initial condition for the forward
tumor problem that recovers a given tumor concentration cP(1) at time t = 1 as good as possible, i.e., we
solve the minimization problem
min
p
JT(p) with JT(p) := Dc(cA, cP) +
βp
2
‖Φp‖22 (9a)
subject to the constraints (7a), (7b), and (7c). This defines the inverse tumor operator
T inv(cP(1)) := p = arg min
q
JT(q). (9b)
Note that the inverse tumor problem does — in contrast to (3b) — only minimize the mismatch between
the observed and the predicted tumor cell population density; the healthy tissue mismatch is not used
as the tumor solver only ’knows’ the altas. In addition, (9) defines a concrete instance for the tumor
regularization operator Sp in (3). Neglecting the boundary conditions, the Lagrangian of (9) reads
LT (cA, p, α) = JT(p) + 〈α(0), cA(0)−Φp〉L2(ΩB) +
∫ 1
0
〈α, ∂tcA −∇ · k∇cA − ρcA (1− cA)〉L2(ΩB) dt
We require vanishing variations of the Lagrangian LT with respect to the inversion variable p for an
admissible solution to (9). This yields the first order optimality condition of the tumor problem:
tumor forward δαLT = 0 : given by (7) (10a)
tumor adjoint δcALT = 0 : −∂tα−∇ · k∇α− αρ+ 2αρcA = 0 in ΩB × [0, 1) (10b)
δcA(1)LT = 0 : cP(1)− cA(1)− α(1) = 0 in ΩB, (10c)
tumor inversion δpLT = 0 : βpΦTΦp−ΦTα(0) = 0 in ΩB, . (10d)
Similarly to the forward problem, the adjoint equation are discretized by extending k and setting ρ = 0
in Ω \ΩB and using periodic boundary conditions in ∂Ω.
3.2. The Registration Problem
The input for our formulation are not image intensities (Mang and Biros, 2015, 2016; Mang and
Ruthotto, 2017; Mang and Biros, 2017) but the probability maps for tissue classes (see (1); WM, GM, CSF,
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and tumor). The formulation we propose here is suited for general problems that involve the registration
of vector fields. The template image (image to be registered) mT : Ω¯→ R3 is given by the probability maps
of the patient’s healthy anatomy in all areas except the part hidden by the tumor. We treat the probability
map for the tumor, cT(x), as an individual entity to make the coupled formulation in (3) more accessible.
We register the three probability maps for healthy tissue and the tumor concentrations.
Advective Image Transformation (Forward Problem). Given some template image mT(x), some tu-
mor concentration cT(x), and a stationary velocity field v(x), the forward problem describes the advective
transformation of mT and cT in a pseudo-time interval [0, 1]:
∂tmP +∇mP v = 0 in Ω× (0, 1], (11a)
mP(0) = mT in Ω, (11b)
∂tcP +∇cP · v = 0 in Ω× (0, 1], (11c)
cP(0) = cT in Ω (11d)
with periodic boundary conditions. We augment this formulation by an additional constraint on the
divergence of v to better control the Jacobian of the computed deformation map (see (Mang and Biros,
2016) for additional details):
div v = w in Ω, (11e)
Solving (11) defines the implicitly given operator
Rfwd (v, mT , cT) := (mP(1), cP(1)) (12)
that maps the template images mT and cT to images mP and cP defined at pseudo-time t = 1. For sim-
plicity, we will later slightly abuse our notation and use the operator Rfwd also for the advection of only
m, c or one of the components of m, i.e., mWM, mGM, or mCSF.
Image Registration (Inverse Problem). In the inverse problem, i.e., the actual image registration, we
look for a velocity v that advects the given template (patient) images to images that are as close as possible
to the corresponding images in the atlas brain (denoted with a subscript A). That is, we solve the following
minimization problem:
min
v
JR(v) with JR(v) := Dm(mA, mP) +Dc(cA, cP) + βvSv(v) + βwSw(w) (13a)
subject to (11). The regularization in (13a) is a smoother for v and w and given by an H1-seminorm for v,
and an H1-norm for w (i.e., for div v according to (11e)), respectively:
Sv(v) = 12
∫
Ω
3
∑
i=1
|∇vi(x)|2 dΩ, Sw(w) = 12
∫
Ω
|∇w(x)|2 + |w|2 dΩ. (13b)
Overall, this defines the (inverse) image registration operator
Rinv (mA(1), cA(1), mT , cT) := v = arg min
u
JR(u). (13c)
The Lagrangian for our image registration problem reads
LR (cP, mP, v,λm,λc) = JR(v)
+
∫ 1
0
〈λm, ∂tmP +∇mP v〉L2(Ω)3 dt + 〈λm(0), mP(0)−mT〉L2(Ω)3
+
∫ 1
0
〈λc, ∂tcP +∇cP · v〉L2(Ω) dt + 〈λc(0), cP(0)− cT〉L2(Ω)
+
∫ 1
0
〈ν, div v− w〉L2(Ω) dt.
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Taking variations, we obtain the first-order optimality conditions (Mang and Biros, 2016) for the registra-
tion problem:
registration forward δλm ,λcLR = 0 : given by (11) (14a)
registration adjoint δmPLR = 0 : −∂tλm − div (λm ⊗ v) = 0 in U, (14b)
δmP(1)LR = 0 : mA(1)−mP(1)− λm(1) = 0 in Ω, (14c)
δcPLR = 0 : −∂tλc − div (λcv) = 0 in U, (14d)
δcP(1)LR = 0 : cA(1)− cP(1)− λc(1) = 0 in Ω, (14e)
registration inversion δvLR = 0 : βv ∇v +K[
∫ 1
0
(∇mP)Tλm +∇cP λc dt] = 0 in Ω. (14f)
As mentioned before, the operator K is a pseudo-differential operator and comes from an elimination
step for the inversion variable w in (3h). For the case of exact incompressibility (w = 0), it is the Leray
projection K(u) := u + ∇ ∇−1div u; for a non-zero w, the projection operator becomes slightly more
involved; we refer to (Mang and Biros, 2015, 2016) for additional details.
4. Numerical Methods
The main contribution of this paper is a Picard iteration scheme for (3): Instead of solving (3) using
a gradient descent or Newton scheme, we use a modular approach, in which we combine tumor growth
inversion and diffeomorphic registration models in an (interleaved) Picard iteration scheme. This scheme
iteratively improves both the tumor initial condition’s parametrization p and the registration velocity v.
This allows us to establish a coupling of both components in an easy, stable, modular, and efficient way;
the submodules can be exchanged as required. For instance, our simple tumor solver can be replaced
by more sophisticated approaches. Our results presented in §5 demonstrate that the Picard iteration is a
powerful approach that reduces the gradient as given in (6).
The algorithms for the individual subblocks have been published in (Mang and Biros, 2015, 2016; Gho-
lami et al., 2017, 2016b,a; Mang et al., 2016; Mang and Biros, 2017). The main ingredients can be described
as follows: (i) All PDEs are spatially discretized in Ω = [0, 2pi]3. (ii) All spatial derivatives (∇, div ,
and higher derivatives) are computed using 3D Fourier transforms. (iii) Although in the formulation
we present the derivatives in the strong form, in our implementation we use a discretize-then-optimize
approach for the tumor equations and an optimize-then-discretize approach for the registration. (iv) The
solution of pure advection equations is done using a semi-Lagrangian time-stepping scheme to avoid
stability issues and small time-steps. (v) We use Krylov and matrix-free Newton methods for linear and
nonlinear solvers. (vi) We use a Picard iteration scheme for the coupled optimization problem, without
line search6.
In the following subsections, we give more details on the proposed Picard iteration scheme, and then
give a short overview of the numerical methods used to solve the tumor and image registration forward
and inverse problems.
4.1. The Picard Iteration Algorithm
To initialize our Picard iteration, we start with an initial guess for p ∈ Rnp and v (both zero), compute
the center of mass of the given patient tumor cT and place the Gaussian basis functions for the tumor
initial condition parametrization as a regular grid around the center of mass. In our current algorithm,
the grid of Gaussian basis functions is fixed throughout the Picard iterations, i.e., we do not re-compute
the center of mass of the tumor or advect the Gaussian basis functions with the velocity v (this is ongoing
work). The algorithm per Picard iteration executes the following steps:
6The Newton-type iterations for the sub-problems registration and tumor inversion are enhanced with a globalizing line search
method.
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1. Given some p, grow a tumor in the atlas space. This seeds the atlas brain with a tumor; update the
probability maps at t = 1 in the atlas space using (3i). To define the Picard iteration, it is useful to
introduce the operator G
G(cA(1)) := (mA(0)(1− cA(1)), cA(1)) . (15)
2. Register the probability maps (for the anatomical regions and the tumor) given for the patient’s
image with the updated probability maps in the atlas space.
3. Use the computed velocity v to transport the patient data (probability maps for the anatomical
regions and the tumor) to the reference atlas space. This gives us a new mP(1) and cP(1).
4. Use the transported (i.e., updated) cP(1) within the tumor inversion to find a better p.
5. Check for convergence. If the convergence criteria are fulfilled, stop. If not, go back to step 1 (i.e.,
continue iterating).
Some important facts to note are: (i) We use the solution v from the former iteration as an initial
guess for the next iteration to reduce the runtime (warm start). (ii) We perform a continuation in the
regularization parameter βv (we start with a large value and successively reduce it). We explain this
below. (iii) We do not have a proof for the convergence of the proposed Picard scheme to a minimizer
of the fully-coupled optimization problem in (3). Such a proof is beyond the scope of the present paper
and remains for future work. We provide numerical evidence that shows that our scheme reduces the
gradient of the fully-coupled problem. We discuss this below.
Using the operators defined in §3, the described algorithm corresponds to the Picard iteration
pk+1=T inv ◦ Rfwd
(
Rinv
(
G ◦ T fwd(pk), mT , cT
)
, cT
)
for the parametrization p of the tumor initial conditions cA(0) in the atlas brain with probability maps
mT and cT for an individual patient as input (we use Rfwd here to only advect the patient’s tumor cT).
We have implemented the gradient of the coupled problem in §3 in order to verify that our Picard it-
eration actually reduces the gradient of the global optimization problem. An implementation of a scheme
that iterates simultaneously on both control variables (i.e., solves the global problem), requires more work
and will be addressed in a follow-up paper. We show experimentally in various settings that our algo-
rithm is effective and generates registration results that are in excellent agreement with the patient data.
Next, we give additional details on the numerical methods used in SIBIA.
Parameter continuation. We use a combination of Tikhonov-type regularization and parameter con-
tinuation (additional details can be found in (Mang and Biros, 2015)) not only to stabilize the registration
problem, but also to identify an adequate regularization parameter βv for the H1-Sobolev norm for v in
every Picard iteration as follows. We specify a lower admissible bound on the determinant of the defor-
mation gradient and start the Picard iteration with β0v = 1. In each iteration k, the candidate βkv is reduced
by one order of magnitude until the specified lower bound for the determinant of the deformation gra-
dient is breached for a candidate βkv. The registration solver disregards the associated solution, sets the
candidate value for βkv to βkv ← βk−1v − (βk−1v − βkv)/2 and restarts the inversion with the velocity of the
former Picard iteration as initial guess. This process is repeated until the lower bound for the determinant
of the deformation gradient is no longer violated. If no violation of the determinant of the deformation
gradient was detected during the registration solve, we finalize the current Picard iteration and proceed
with the next iteration.
Stopping conditions. We finalize our Picard iteration either if βv reaches the prescribed minimum7 or
if the requested βv results in a violation of a user defined lower bound on the determinant of the defor-
7This lower bound is chosen based on numerical experience and is a safeguard against numerical instabilities that can occur if v
becomes highly irregular (see (Mang and Biros, 2017) for a discussion).
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mation gradient (see above for further explanation). In both cases, we execute two additional iterations
with the final value for βv.
4.2. Numerics for the tumor inversion and registration sub-blocks
The optimality conditions of both (9a) and (13a) are complex, multi-component, non-linear opera-
tors for the state, adjoint, and control fields. We employ an inexact, globalized, preconditioned Gauss–
Newton–Krylov method for both problems. In reduced space methods, the second order optimality
conditions have a very similar structure as the first order optimality conditions; we can employ the same
numerical strategies we use for the solution of the PDE operators in the first order optimality conditions
(see below). We refer to (Gholami et al., 2016b; Mang and Biros, 2015, 2017; Mang et al., 2017) for details
on the reduced space Hessian system and its discretization.
Numerical solution and discretization of the PDE operators. To discretize forward and adjoint tumor
and registration problems in space and time, we use regular grids consisting of N0×N1×N2, Ni ∈N grid
points. For all spatial differential operators, we use a spectral projection scheme as described in (Gholami
et al., 2017; Mang et al., 2016). The mapping between the spatial and spectral coefficients is done using
FFTs (the implementation of the parallel FFT library is presented in (Gholami et al., 2016a)). Correspond-
ing to the spectral collocation scheme, we assume that the functions in our formulation (including images)
are periodic and continuously differentiable and apply filtering operations and periodically extensions of
the discrete data to meet these requirements.
To solve the forward and adjoint tumor problem, we use an unconditionally stable, second-order
Strang-splitting method, where we split the right-hand side of (7a) and (10b) into diffusion and reaction
(see (Hogea et al., 2008a; Gholami et al., 2016b) for details). The diffusion sub-steps are solved using an
implicit Crank–Nicolson method. The solver is a preconditioned conjugate gradient method with a fixed
tolerance of 1E−6. The reaction sub-steps are solved analytically. We enforce a positivity constraint on
the initial tumor concentration before we apply the forward operator to make sure that c(x, t) is in [0, 1]
for all x ∈ Ω and t ∈ [0, 1]. This thresholding operation is necessary since the parametrization allows for
negative concentrations for the initial condition cA(0) (the coefficient vector p can have negative entries)
and the logistic growth function would amplify these negative values in time.
In the image registration module, we solve the hyperbolic transport equations in (11) based on a
semi-Lagrangian scheme (Mang et al., 2016; Mang and Biros, 2017). Semi-Lagrangian schemes are a hy-
brid between Lagrangian and Eulerian schemes. They are unconditionally stable and, like Lagrangian
schemes (see (Mang and Ruthotto, 2017) for an example in the context of diffeomorphic registration),
require the evaluation of the space-time fields that appear in our optimality conditions at off-grid loca-
tions defined by the characteristic associated with v. We compute the values of these space-time fields
at the off-grid locations with a cubic Lagrange polynomial interpolation model. The time integration for
computing the characteristic and for the solution of ordinary differential equations along it (if necessary)
is based on a second order accurate Runge–Kutta scheme. We refer to (Mang et al., 2016; Mang and Biros,
2017) for a precise definition of these computations.
Newton–Krylov solver. We initialize our solvers for both reduced gradient systems (10d) and (14f)
with a zero initial guess and use an inexact, globalized, preconditioned Gauss–Newton–Krylov method.
We terminate the tumor inversion if the relative change of the norm of the reduced gradient in (10d) is
below a user defined threshold opttolT > 0. The reference gradient is the gradient obtained for the zero
initial guess for p in the first Picard iteration. For the registration problem, we use a combination of the
relative change of (i) the norm of the gradient in (14f), (ii) the objective in (13a) and (iii) the control variable
v, all controlled by a single parameter opttolR > 0, as a stopping criterion. We also specify a maximal
number of Newton iterations (maxitN,T and maxitN,R) and a lower bound of 1E−6 for the absolute norm
of the gradient as a safeguard against a prohibitively high number of iterations. Details for the stopping
conditions can be found in (Mang and Biros, 2015; Modersitzki, 2009); see (Gill et al., 1981, 305 ff.) for a
discussion.
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We invert the inner linear KKT systems using a matrix-free PCG method. We terminate the PCG
method when we either reach a predefined tolerance for the relative residual norm of the PCG method or
exceed the maximum number of iterations (maxitK,T and maxitK,R). We perform inexact solves (Dembo
and Steihaug, 1983; Eisentat and Walker, 1996) with a tolerance that is proportional to the norm of the
reduced gradient of our problem. The key idea here is to not invert the Hessian accurately if we are
far from an optimum (large gradient norm). Details about this approach can be found in (Nocedal and
Wright, 2006, p. 165ff.).
4.3. Parallel Algorithms and Computational Kernels
Our parallel implementation is described in detail in (Mang et al., 2016; Gholami et al., 2017). We
use a 2D pencil decomposition for 3D FFTs (Grama et al., 2003; Czechowski et al., 2012) to distribute the
data among processors. We denote the number of MPI tasks by P = P0P1. Each MPI task gets a total
of N0/P0 × N1/P1 × N2 values. We use the open source library AccFFT (Gholami et al., 2016a), which
supports parallel FFT on CPU and GPU for both single and double precision computations. For parallel
linear algebra operations, we use PETSC as well as it’s optimization interface TAO (Balay et al., 2016;
Munson et al., 2015). The other computational kernel besides FFTs is the cubic Lagrange polynomial
interpolation model used for the semi-Lagrangian time integration of hyperbolic transport equations. We
refer to (Mang and Biros, 2016; Gholami et al., 2017) for additional details on the parallel implementation
of this interpolation kernel. We provide an algorithmic complexity analysis for the registration in (Mang
et al., 2016) and for the FFT in (Gholami et al., 2016b).
5. Numerical Experiments
We test the performance of our method on synthetically generated and clinical datasets. Both are
based on real MR neuroimaging data for the brain tissue probability maps.
ATAV. This first class of synthetic test cases is used as a proof of concept to assess the convergence
of our Picard scheme, its robustness with respect to the tumor model, and the sensitivity of tumor re-
construction quality in terms of the tumor model and its parameters. It uses analytic tumor and analytic
velocity (fully synthetic; ground truth for tumor parameters and velocity is known); see §5.2 for details. It
comes in three different flavours: (i) ATAV-REAC with reaction only and diffusion disabled, (ii) ATAV-DIF
with reaction-duffusion model, and (iii) ATAV-LD with reaction only and diffusion disabled and a small
number np of Gaussian basis functions for the initial condition.8
RTRV. This second second class of test cases uses real clinical images used in the study described
in (Gooya et al., 2013). It uses real patient data, diffusion disabled and enabled; see §5.3 for details.
5.1. General Setup
Common Parameters. We list all model and numerical parmeters that are common to all test cases in
Tab. 1 and those that are specific for the test cases in Tab. 2. In the following, we shortly motivate some
of the more involved choices:
βp has been determined experimentally for a purely synthetic test case with image resolution Ni = 128
and np = 125 Gaussian basis function. For variations of Ni and np in our test cases, we observed that
the inversion is not sensitive with respect to βp. Accordingly, we fixed it for all test cases. Smaller values
did not further reduce the tumor mismatch in our Picard iteration scheme. To initialize the Gaussian
basis, the sub-domain for the grid of basis functions is chosen a priori for the synthetic test cases and
determined automatically for the real patient data (cases RTRV) to cover the actual tumor volume in an
optimal way: We set the center of the grid for the parameterization to the center of mass of the tumor. The
8LD stands for low-dimensional. That is, we use only very few active Gaussian basis functions with a limited support in a small
neighbourhood surrounding the center of mass of the patient’s tumor. For the other test cases, we allow the grid for the Gaussian
to cover the entire area identified as tumor in the patient data.
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support of the domain covered by the basis functions is the `∞-ball that covers the entire patient’s tumor
in R3. We adjust the standard deviation σ of the Gaussian functions and the distance of their centers
automatically. The values are chosen such that their quotient remains constant, and equal to the value
used in the synthetic cases. This allows us to ensure a similar conditioning for Φ and to use a fixed βp.
The choice for np depends on the appearance of the patient’s tumor (shape and size). We need to be
able to parameterize sufficiently complex initial conditions to recover tumors with a complex appearance.
Accordingly, we invert for a varying number of parameters np on a case-by-case basis (np ∈ {8, 125, 343}
(see Tab. 2). For the class of synthetic test cases (ATAV), we use an image resolution of 1283 to be able to
perform more experiments in limited time, for the real patient data, we use 2563 to ensure high accuracy.
Table 1: Common parameters used in all test cases: opttolR, opttolT are the convergence tolerances for registratioin and tumor inversion ((14f)
and (10d)); βp is the regularization parameter for the tumor inversion (see (9a)); d is the spacing between the Gaussian basis function, σ their
standard deviation; β0v and βminv are the initial and final values for the β-continuation scheme as described in 4.1 applied in image registration,
determined based on which values have been shown to yield best results in numerical tests for the RTRV test problem.
opttolR opttolT βp d β
0
v β
min
v
1E−3 1E−3 2.50E−4 1.5σ 1 1E−3
Data. For the generation of the synthetic cases, we use normal brain imaging data obtained at the
University of Pennsylvania. For the test case on real imaging data, we use the data available after the first
iteration of GLISTR (Gooya et al., 2011, 2013; Bakas et al., 2015). The data for these results are the patient
data used in the study presented in (Gooya et al., 2013; Bakas et al., 2015). We consider six datasets from
this repository (patient IDs: AAMH, AAAN, AAAC, AAMP, AAQD and AAWI). The original datasets
have more labels than we use in our Picard iterations. In particular, they contain background (BG), white
matter (WM), gray matter (GM), cerebellum (CB), cerebrospinal fluid (CSF), ventricles (VE), edema (ED),
enhancing tumor (ENH), and necrotic tumor (NEC). We construct the labels (WM), (GM), (CSF), (BG) and
(TU) by integrating (i) (CB) into (BG), (ii) (VE) into (CSF), and (iii) (ENH), (NEC) and (ED) into (TU).
For all brains, we use the labels white matter (WM), gray matter (GM), cerebrospinal fluid (CSF), and
background (BG). The motivation for introducing an additional label BG is technical. We have to ensure
the partition of unity across all probability maps for each x in Ω, i.e., all labels have to sum up to one. For
example, for the atlas data at t = 1 we have
∀x ∈ Ω : cA(x, 1) +
4
∑
i=1
mA,i(x, 1)
!
= 1
Note that mBG is not used as a label in the image registration formulation (13a). Glial matter is integrated
in BG.
Performance Measures. We perform the registration from the patient space to the atlas space. However,
we report all performance measures in the patient space, since the patient space is the relevant space from
an applications point of view (for atlas based segmentation).9 An important point to note here is that
velocity based image registration offers an immediate access to the inverse of the deformation applied to
an image; we can essentially solve the forward problem with a negative velocity to obtain the action of
the inverse deformation map. We use the following measures to assess the performance of our approach:
The relative mismatch/residual µB,L2 between patient anatomy and atlas anatomy after registration (i = 1:
GM; i = 2: WM; i = 3: CSF), and the relative mismatch/residual µT,L2 between patient tumor and atlas
9If we perform cohort studies, this is different (see (Gooya et al., 2013) for an example).
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Table 2: Summary of the parameters for the generation of the synthetic test cases and the inversion. We report values for the following
parameters: Ni , i = 1, 2, 3 denotes the grid size used for the discretization of the problem; ρw and ρg are the characteristic reaction factors for
white and gray matter, ρ f is the overall reaction scaling factor (see §3.1); kw and kg are the characteristic diffusion parameters for white and
gray matter, k f the overall scaling parameter for the isotropic part of the inhomogenious diffusion coefficient for net migration of cancerous cells
into surrounding tissue; np is the number of Gaussian for the parameterization of the tumor initial condition, σ is the standard deviation of the
associated Gaussian basis functions, and maxiti = (maxiti,N , maxiti,K) denotes the maximum number of Newton iterations and Krylov iterations
(for the KKT system) for the tumor inversion (i = T) and registration (i = R), respectively,
ATAV-REAC ATAV-DIF ATAV-LD RTRV
Ni 128 128 128 256
ρw 1 1 1 1
ρg 0 0 0 0.2
ρ f 15 {5, 10, 15} {5, 10, 15} {0, 5, 10, 15}
kw 1 1 1 1
kg 0 0 0 0.1
k f 0 {0, 1E−2} {1E−2, 1E−1} {0, 1E−2}
np 125 125 8 {125, 343}
σ pi/10 pi/10 pi/15 auto
maxitT (50, 100) (30, 60) (30, 60) (30, 30)
maxitR (50, 80) (50, 80) (50, 80) (10, 20)
tumor after registration:
µB,L2 :=
∑3i=1 ‖Rfwd(−v, mA,i(1))−mT,i‖2
∑3i=1 ‖mA,i(0)−mT,i‖2
µT,L2 :=
‖Rfwd(−v, cA(1))− cT‖2
‖cT(1)‖2
The Dice coefficient DICEl,B for the individual label maps (generated by thresholding; see below) associ-
ated with the probability maps for l = WM, l = GM, and l = CSF, for the patient and atlas anatomy, as
well as the average Dice coefficient DICEB across all labels:
DICEl,Bc := 2
|H(Rfwd(−v, mA,l(1))) ∩ H(mT,l)|
|H(Rfwd(−v, mA,l(1)))|+ |H(mT,l)| , DICEB =
3
∑
l=1
DICEl,B/3
where | · | is the cardinality of the set and H is a characteristic function of a label with threshold 0.5, i.e.,
H(u(x)) :=
{
1 for u(x) ≥ 0.5,
0 else,
for all x ∈ Ω. We also report values for the Dice coefficient computed for the probability maps of the
tumor, denoted by DICET . Further, we monitor the relative change of the gradient for the coupled problem
(see §3) for the final iteration k:
‖g‖rel := ‖gk‖2/‖g0‖2.
where gk is the gradient of the coupled optimization problem (3) after the kth Picard iteration and g0
the gradient for the initial guess. Finally, the relative `2-error for the computed velocity and the initial
condition (under the assumption we know the true velocity v? and true tumor parameters p?; synthetic
test problem) at the final (kth Picard) iteration:
ev,L2 := ‖v? − vk‖2/‖v?‖2 ec0,L2 := ‖c?A(0)− ckA(0)‖2/‖c?A(0)‖2.
Hardware. The runs for all test cases were executed on the Tier-1 supercomputer HazelHen at the
High Performance Computing Center HLRS in Stuttgart (www.hlrs.de), a Cray XC40 system with a peak
performance of 7.42 Petaflops comprising 7, 712 nodes with Xeon E5-2680 v3 processors and 24 cores on
two sockets per node. The nodes are connected via an Aries interconnect. For data sizes of Ni = 128,
i = 0, 1, 2, we use 3 nodes with 64 MPI tasks and for Ni = 256, i = 0, 1, 2, we use 11 nodes and 256 MPI
tasks.
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5.2. Test Case ATAV
Purpose. This experiment is a proof of concept. We test the numerical accuracy of our scheme, identify
the inversion accuracies we can ideally expect (i.e., the errors we get if we use the forward operators to
generate the observations for our coupled inversion), and study the convergence of our solver.10. With
ATAV-REAC and ATAV-DIF, we in addition test the sensitivity of our approach with respect to pertu-
bations in the model and model parameters. In ATAV-LD, we restruct the admissible initial condition
parametrization for tumor growth to a very low dimensionality in order to exclude fully grown tumors
as initial conditions. We examine, whether this increases the sensitivity of the reconstruction quality for
the tumor with respect to correct model parameters.
Setup. ATAV is based on real brain geometries, but uses a tumor grown with our forward solver in a
synthetically generated patient image. We use a resolution of Ni = 128. We choose p = p?, which defines
cA(0) = c?A(0), grow a tumor in the tumor-free atlas, which gives c
?
A(1), choose v = v
?, deform the
atlas with the grown tumor by advecting the probability maps with the negative velocity v?. This gives
us mT and cT (patient image with tumor). The velocity v? is generated by registering two tumor-free
images of two different individuals (β?v = 1E−4). The center of mass for the synthetic tumor is set to
(x1, x2, x3) = 2pi · (0.285, 0.36, 0.5). As initial condition for the artificial tumor generation, we enable two
of the Gaussians at the center of the grid of Gaussians. See §5.1 for further details on the parameters. As a
baseline, we also report results for the sole registration of the healthy anatomy (i.e., neglecting the tumor
forward solve to generate the data). In addition to that, we quantify the numerical error of our scheme
for solving the transport equations (forward registration). This is done by solving the forward problem
twice, once with the original and once with the reverted (negative) velocity. The associated error is given
by ∥∥cA(1)? −Rfwd (−v?,Rfwd (v?, cA(1)?))∥∥2
‖cA(1)?‖2 = 9.37E−2 (16)
Whereas we disable diffusion (k f = 0) in ATAV-REAC, we use the full tumor model including diffu-
sion (k f , 0) for ATAV-DIF. In ATAV-REAC, the same growth rates ρw, ρg with scaling ρ f and kw, kg with
scaling k f are used for growing the tumor and for the inversion to reconstruct the initial condition. In
ATAV-DIF, we use values for the reaction and diffusion coefficients for the inversion in the Picard itera-
tions, that are either the same or differ from those used for the generation of the tumor. In ATAV-LD,
we use the full reaction-diffusion tumor model and enforce the initial tumor to be small, i.e., only invert
for np = 8 parameters, which results in a grid of 2× 2× 2 Gaussians that cover the true initial condition
of the artificially grown tumor. We expect this to increase the sensitivity of our inversion with respect
to the tumor parameters (we can not fully represent the whole patient tumor purely based on a linear
combination of the basis functions). For the inversion, we again consider a variety of models and model
parameter combinations, which includes the use of the ‘’correct‘’ (ground truth) tumor parameters. We
also consider the case in which we completely neglect the tumor model (i.e., ρ f = k f = 0) and just invert
for the basis.
Results. We report results for the registration of anatomy (without tumor) in Tab. 3. Results for the
inversion in ATAV-REAC are presented in Fig. 2 and assess the reconstruction quality (Dice and residuals)
and the reduction of the reduced gradient with respect to the iteration index. We also report the error
between the ground truth cA(0)? = Φp? and v? and the estimated iterates as well as the relative norm of
the gradient of the fully coupled problem in (3).
For ATAV-DIF, quantitative results for the inversion are shown in Tab. 4, qualitative results can be
found in the supplementary material in Fig. A.9. In addition to reconstruction quality and gradient
10In general, considering real data, our forward model is—at best—a crude approximation of the actual observations. That is, first
of all, we can not expect our registration algorithm to recover a bio-physically meaningful deformation between the brain anatomies
of different subjects (such a model does not even exist). Second, our forward tumor model is far from being realistic (see §3.1 for a
discussion).
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reduction, we list the runtime for the Picard scheme per iteration and the percentage spent in each indi-
vidual solver (tumor and registration), respectively. Note that tumor and registration runtimes do not add
up to 100% as further parts of the code such as the calculation of the reduced gradient and the steering
of the Picard iteration are not included in the measurements.
For ATAV-LD, we show simulation results in Fig. 4 (for sagittal and coronal slices, Fig. A.10) and
report quantitative results in Tab. 5. We plot the trend of the relative tumor mismatch with respect to
the regularization parameter βv for the Sobolev norm for the registration velocity (and by that the Picard
iteration index) in Fig. 3.
Table 3: Reference results for geometry registration only between healthy atlas and healthy patient. The table shows values for the relative
mismatch for the geometry (µB,L2 ) and the associated Dice coefficient DICEB as well as the relative `
2-error for the reconstruction of the velocity
field ev,L2 with respect to the ground truth v
?.
maxitR µB,L2 DICEB ev,L2
(50, 80) 1.78E−1 9.37E−1 3.59E−1
(10, 20) 1.68E−1 9.36E−1 3.14E−1
Table 4: Results for the analytic tumor / analytic velocity with non-zero diffusion (ATAV-DIF) test case; ground truth: (ρ f = 10, ρw = 1,
ρg = 0, k f = 1.00E−2, kw = 1, kg = 0, p = p?, v = −v?). We report values for the (summed) norm of the residual between the respective
probability maps for the different brain tissue classes µB,L2 and tumor µT,L2 in patient space, the mean Dice coefficient for brain tissue DICEB and
tumor DICET , respectively, as well as the relative norm of the gradient ‖g‖rel for the global coupled problem (3). We report results for different
values of ρ f ∈ {5, 10, 15} used in the inversion (ρ f = 10 is the ground truth). We report the time spent per iteration (in seconds; top run) or in
total (in seconds; bottom runs) for the entire Picard inversion, and the amount of that time spent in the tumor inversion and image registration
(in percent (top run); in seconds (bottom runs)), respectively. Note that the latter sums up to less than 100% as we do not explicitly measure
time spent in additional coupling functionality and forward solvers. These runs are performed using 64 MPI tasks on three nodes of HazelHen
(see §?? for details). The top block shows the course of the inversion with respect to the Picard iteration index for the correct parameters (ground
truth) for ρ f and k f . The four rows on the bottom show the final result for our Picard scheme for different parameter and model combinations.
iterations βv µB,L2 DICEB µT,L2 DICET ‖g‖rel Tit [s] Ttuinv [%] T
reg
inv [%]
non-zero diffusion with ground truth parameters ρ f = 10, k f = 1E−2
ref – 1.00 7.14E−1 1.00 0.00 1.00
1 1 9.32E−1 7.32E−1 1.00 0.00 9.94E−1 2.11E+3 99.7 0.2
2 1E−1 6.52E−1 8.01E−1 2.08E−1 8.56E−1 7.45E−2 2.88E+2 96.0 2.1
3 1E−2 3.79E−1 8.88E−1 1.47E−1 9.12E−1 3.87E−2 3.94E+2 91.8 6.9
4 1E−3 1.75E−1 9.39E−1 8.08E−2 9.63E−1 2.45E−2 3.98E+2 72.7 26.1
5 1E−4 1.60E−1 9.48E−1 5.93E−2 9.78E−1 1.77E−2 2.00E+2 35.4 62.1
6 1E−4 1.60E−1 9.48E−1 5.77E−2 9.77E−1 1.72E−2 1.34E+2 46.6 49.6
7 1E−4 1.60E−1 9.47E−1 5.63E−2 9.76E−1 1.73E−2 7.10E+1 0.0 93.0
varying ρ f ∈ {5, 10, 15}, k f = 1E−2, ground truth ρ f = 10, k f = 1E−2 Ttotal [s] Ttuinv [s] T
reg
inv [s]
ρ f = 5 1E−4 1.61E−1 9.46E−1 6.48E−2 9.67E−1 2.21E−2 4.37E+3 3.95E+3 3.97E+2
ρ f = 10 1E−4 1.60E−1 9.47E−1 5.63E−2 9.76E−1 1.73E−2 3.60E+3 3.17E+3 4.01E+2
ρ f = 15 1E−4 1.61E−1 9.48E−1 6.39E−2 9.72E−1 1.41E−2 3.96E+3 3.53E+3 4.00E+2
ρ f 10, k f = 0, ground truth ρ f = 10, k f = 1E−2 Ttotal [s] Ttuinv [s] T
reg
inv [s]
ρ f = 10 1E−4 1.60E−1 9.48E−1 5.95E−2 9.71E−1 1.74E−2 4.25E+2 2.25E+1 4.01E+2
Observations. The most important observation are (i) that the reconstructed data (tumor and regis-
tered anatomy) is in excellent agreement with the patient data, and (ii) we are able to reduce the reduced
gradient (6) by two orders of magnitude in less than iterations of our Picard scheme for ATAV-REAC and
significantly more than a factor of 50 for all experiments in ATAV-DIF and ATAV-LD.
The numerical error for the advection in (16) is 9.37E−2. The relative mismatch for the anatomy
obtained for our iterative Picard scheme is in the order of the advection error for the forward image
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iteration βv µB,L2 DICEB µT,L2 DICET ev,L2 δv ec0,L2 ‖g‖rel
initial – 1.00 7.10E−1 1.00 0.00 1.00 – 1.00 1.00
1 1 9.37E−1 7.27E−1 1.00 0.00 9.60E−1 – 2.54E−1 9.98E−1
2 1E−1 6.30E−1 8.01E−1 2.26E−1 8.63E−1 8.50E−1 9.77E−1 2.05E−1 5.91E−2
3 1E−2 3.67E−1 8.88E−1 1.47E−1 9.19E−1 6.31E−1 9.33E−1 1.65E−1 3.07E−2
4 1E−3 1.71E−1 9.40E−1 7.91E−2 9.66E−1 3.35E−1 6.62E−1 1.40E−1 1.95E−2
5 1E−4 1.57E−1 9.47E−1 6.55E−2 9.74E−1 3.59E−1 3.65E−1 1.36E−1 1.32E−2
6 1E−4 1.57E−1 9.47E−1 6.39E−2 9.73E−1 3.59E−1 1.45E−5 1.33E−1 1.21E−2
7 1E−4 1.57E−1 9.47E−1 6.29E−2 9.73E−1 3.59E−1 1.45E−5 – 1.21E−2
Figure 2: Results for the analytic tumor / analytic velocity reaction-only (ATAV-REAC) test case; ground truth: (ρ f = 15, ρw = 1,
ρg = 0, k f = 0, p = p?, v = −v?). The figure shows probability maps for the labels of the healthy atlas brain and the patient brain with tumor
generated from a tumor grown in the atlas and known atlas to patient advection velocity (see text for details; axial-slice 64). We show the initial
configuration for the problem (top row; iteration k = 1), the final configuration after joint registration and tumor inversion (middle row; iteration
k = 7; the atlas image probability maps are transported to the patient space), and the target patient data (reference image; bottom row). Each row
contains (from left to right) the probability maps for WM, GM, CSF, and TU, the residual differences (if available) between the probability maps,
and a hard segmentation based on the given probabilities for the individual tissue classes. The table on the bottom provides quantitative results
for the inversion. We report the average mismatch for the probability maps for the brain tissue labels µB,L2 and the tumor µT,L2 , the mean DICE
coefficient for brain tissue DICEB and tumor DICET , respectively. The reconstruction quality is given in terms of convergence of vk and ckA(0)
towards the ground truth v? and c?A(0), respectively (ev,L2 and ec0,L2 ). We can not expect this error to go to zero for several reasons. First, we
loose information when we construct the test case (zero gradients in the intensity of the image), second our numerical solver introduces errors (in
particular, the solver for the transport equations). We in addition to that report the change in update in the velocity v across successive iterations
δv = ‖vk − vk−1‖/‖vk−1‖. Finally, we also list the relative norm of the gradient for the coupled problem in (3) (‖g‖rel).
registration problem. We can also see that the reconstruction of cA(0)? and cA(1)? seems to be bounded
by this error. In fact, due to the advection error that leads to a mismatch in this order in the atlas domain,
this is the best we can expect without over-fitting the data. Similar observations can be made if we
compare the inversion results with the results obtained for the registration for healthy brains (neglecting
the tumor simulations) reported in Tab. 3. Hence, the quality of tumor reconstruction is comparable to the
quality of pure image registration between the healthy geometries. This is an excellent result that clearly
demonstrates the potential of our approach. The obtained Dice coefficient for the brain anatomy is in the
order of what we see for the sole registration of healthy anatomies.11 Note that the mismatch between
the true velocity v? and the recovered velocity vk reported for ATAV-REAC is due to the fact that image
11In fact, it is even slightly better for ATAV-REAC. This slight increase might be a consequence of numerical inaccuracies in our
scheme, discrepancies in the number of Newton-steps and Krylov iterations taken.
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Figure 3: Mismatch reduction as a function of the regularization parameter βv for the analytic tumor with analytic velocity, diffusion and
low-dimensional initial condition (ATAV-LD) test case; ground truth: (ρ f = 15, ρw = 1, ρg = 0, k f = 1.00E−1, kw = 1, kg = 0, p = p?
(in patient domain), v N/A). We use an initial condition parameterized with only np = 8 Gaussians (σ = pi/15) and an analytic tumor with
non-zero diffusion. The plot shows the relative mismatch for the tumor probability map µT,L2 in patient space. Note that we reduce βv by a factor
of ten in each Picard iteration; the plot shows the mismatch reduction over the Picard iterations if read from right to left.
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Figure 4: Tumor and brain labels for the analythic tumor with analythic velocity with non-zero diffusion and low-dimensional initial
condition (ATAV-LD) test case; ground truth: (ρ f = 15, ρw = 1, ρg = 0, k f = 1.00E−1, kw = 1, kg = 0, p = p? (in patient domain), v
N/A); for the ’correct’ tumor parameters ρ f = 15, k f = 1.00E−1, and the two different settings ρ f = 15, k f = 5.00E−1 and ρ f = k f = 0.
registration is an inherently ill-posed problem: the velocity can only be reconstructed exactly in image
areas with non-zero gradients and if there are only non-zero intensity differences between the images to
be registered in areas that do correspond to one another12. In addition, we ask for the reconstruction of a
vector field from scalar data.
The Dice coefficient for the brain anatomy increases from 7.10E−1 to 9.47E−1 in ATAV-REAC, where
we obtain a final Dice coefficient of 9.73E−1 for the tumor. The results for ATAV-DIF and ATAV-LD show
that the used model and the dimensionality of the initial conditions do not have a significant impact on
the quality of the inversion (Dice and mismatch).
We can furthermore see that we can significantly reduce the norm of the reduced gradient (6) to
1.21E−2. We can also see that once we have reached the target regularization parameter βv = 1E−4 we
do not make any more progress. The update for the velocity tends to zero, the changes in the reduced
gradient are small and the error measures (residual and Dice) do no longer change significantly.
For ATAV-DIF, we see that we obtain a slightly better mismatch (5.63E−2) and Dice coefficient (9.76E−1)
for the tumor probability map if we use the correct ρ f . These results suggest that we can identify the cor-
rect ρ f if we run multiple inversions for the initial condition. However, we note that these differences
are small (the mismatch is between 5.95E−2 and 5.63E−2 and the Dice is between 9.71E−1 and 9.76E−1,
12As in any formulation based on an L2-distance functional, it is the mismatch between the reference and template image and the
gradient of the deformed template image that drive the optimization (see (14f)).
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Table 5: Results for the analytic tumor with analytic velocity with diffusion and low-dimensional initial condition (ATAV-LD) test
case; ground truth: (ρ f = 15, ρw = 1, ρg = 0, k f = 1.00E−1, kw = 1, kg = 0, p = p? (in patient domain), v N/A). We use a low-dimensional
parameterization for the initial condition with np = 8 Gaussians (σ = pi/15). We report the (summed) mismatch for the probability maps for
the brain tissue µB,L2 and tumor µT,L2 in patient space, the mean Dice coefficient for hard segmentations of brain tissue (DICEB) and tumor
(DICET), respectively, and the relative norm of the gradient (‖g‖rel) for the coupled problem (3). We assess the final state of the reconstruction
using different values for ρ f ∈ {5, 10, 15, 20} and k f ∈ {0, 1E−1}. Absolute timings are given for the tumor inversion and image registration,
respectively using 64 MPI tasks on three nodes of HazelHen. Note that the latter sums up to less than the reported total run time as we do not
explicitly measure time spent in additional coupling functionality and forward solvers. We always reach the target value of βv = 1E−4.
ρ k It µB,L2 DICEB µT,L2 DICET ‖g‖rel Ttotal [s] Ttuinv [s] T
reg
inv [s]
initial 1.00 7.18E−1 1.00 0.00 1.00 – – –
0 0 final 1.96E−1 9.45E−1 2.80E−1 8.48E−1 4.16E−2 3.78E+2 3.33 3.77E+2
15 0 1.87E−1 9.46E−1 2.04E−1 9.16E−1 1.70E−2 3.78E+2 2.19 3.78E+2
15 1E−1 1.69E−1 9.48E−1 4.68E−2 9.65E−1 1.73E−2 4.72E+3 4.17E+3 4.59E+2
15 5E−1 1.90E−1 9.41E−1 3.37E−1 4.71E−2 1.78E−2 6.67E+3 5.54E+3 4.29E+2
15 1E−2 1.79E−1 9.47E−1 1.57E−1 9.31E−1 1.51E−2 2.23E+3 1.50E+3 4.31E+2
5 1E−1 1.71E−1 9.46E−1 6.50E−2 9.57E−1 2.45E−2 1.96E+3 1.50E+3 3.87E+2
10 1E−1 1.70E−1 9.47E−1 4.98E−2 9.62E−1 2.01E−2 3.90E+3 2.90E+3 3.73E+2
10 1E−2 1.79E−1 9.47E−1 1.65E−1 9.26E−1 1.91E−2 2.17E+3 1.63E+3 3.66E+2
20 1E−1 1.70E−1 9.48E−1 5.45E−2 9.56E−1 2.02E−2 3.07E+3 2.62E+3 3.88E+2
20 1E−2 1.80E−1 9.47E−1 1.60E−1 9.18E−1 1.20E−2 2.03E+3 4.51E+2 3.78E+2
respectively, for the tumor). Overall, we obtain an excellent agreement between patient data and atlas
data irrespective of the model choice. These observations are confirmed by careful visual inspection of
Fig. A.9 (supplementary material; shows only results for the ‘’correct‘’ tumor parameters). This can be
explained by the parameterization of the initial condition. We can reconstruct complex tumor shapes even
with a simple model. Overall, this indicates that using a reaction-only model might be sufficient for pure
diffeomorphic image registration13, where a comparison of the total run time for the last row in Tab. 4 to
the total runtimes attained when enabling diffusion shows that we can save a factor of 10 in runtime by
disabling diffusion. Another interesting behavior within our scheme is that, during the first few iterations,
most time is spent in the tumor inversion, whereas, as we reduce βv, the registration does most of the
work. This is to be expected, since the runtime of our scheme (more precisely, the condition number of
the Hessian) for diffeomorphic registration, is not independent of βv (Mang and Biros, 2015; Mang and
Ruthotto, 2017).
The most important observation for ATAV-LD is that we can identify the correct pair of diffusion and
reaction rate that has been used to generate the synthetic test based on slightly more pronounced differ-
ences in the overall mismatch and Dice scores than in ATAV-DIF. The sensitivity with respect to changes
in the diffusion parameter k f is larger than with respect to changes in the growth rate ρ f . We expect this
much more pronounced dependence on the diffusion model if we parameterize the initial condition on
a grid with a smaller support, since we need the cancerous cells to diffuse to areas more distant to the
tumor center in order to be able to reconstruct the whole tumor. The trend of the relative mismatch for
the tumor in Fig. 3 highlights this effect. The curves almost cluster in terms of the different choices for
the diffusion coefficient; we overall achieve significantly better mismatch if we choose the correct diffu-
sion coefficient. We can also see that the curves plateau much earlier in cases where we use the wrong
parameter combinations. The tumor mismatch takes values between 3.37E−1 and 4.68E−2 with a Dice
score of 4.71E−2 to 9.65E−1.
Conclusion: We conclude that our Picard scheme is efficient and converges to a valid (local) minimum
in the search space (we reduce the relative global gradient, the distance measure, and significantly increase
13This is clearly not the case when targeting the design of computational framework to aid clinical decision making by generating
model based prediction of a patient’s future tumor state. In this case, we quite certainly have to use more complex, high-fidelity
models. We discuss this in more detail in §6.
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the Dice coefficient). We attain an excellent agreement between the data (patient tumor and geometry)
and the predicted state (transported atlas geometry and predicted tumor) with a final Dice coefficient of
9.47E−1 and 9.73E−1 for the labels of the anatomy and tumor In ATAV-REAC and only slightly worse
values in ATAV-DIF and ATAV-LD.
The integration of a diffusion model into our inversion is very costly, at least for our current imple-
mentation. Designing a more efficient forward solver for the diffusion operator requires more work. We
could demonstrate that our parameterization of the initial condition allows us to generate high-fidelity
registration results, especially for the healthy anatomy, irrespective of the model that has been used to
generate the data. These are clearly preliminary results, but they provide some evidence that reaction-
only models might be sufficient for pure image registration (something that is quite certainly not the case
if we target parameter identification and tumor growth prediction) (Hogea et al., 2008a).
We can also observe that there are subtle differences in the reconstruction quality of the tumor if we use
the ‘’correct‘’ growth rate for the inversion for ATAV-DIF, that are more pronounced in ATAV-LD. Overall,
we conclude that we (i) can neglect the diffusion model in the context of diffeomorphic registration and
compensate the resulting loss in accuracy by a higher-dimensional Gaussian basis, (ii) might be able
to identify appropriate growth rates if we run multiple inversions for different parameters with a low-
dimensional Gaussian basis .
5.3. Test Case RTRV
Purpose. We test our approach on real data of patients diagnosed with glioma tumors and study the
registration quality for a variety of parameter choices for the tumor growth model.
Setup. This test scenario consists of real patient brains with real tumors for which we do not know
any parameters. The patient datasets are the first proposal for a patient segmentation produced in the
first iteration of GLISTR (Gooya et al., 2013). We provide additional details about this databasis in §5.1.
We have to identify the support of the domain spanned by the Gaussian basis functions for the tumor
initial condition parametrization as well as their spacing d, and the standard deviation σ for any unseen
patient. This is done automatically. As some of the real tumors are multifocal, we use np = 343 Gaussians
in our first set of experiments on all six brains for the initial condition parametrization. In contrast to the
synthetic test cases ATAV-REAC, ATAV-DIF and ATAV-LD, we allow the tumor to grow also in gray mat-
ter instead of in white matter only, but with a reaction parameter that is five times smaller than in white
matter (see Tab. 2 for details). We use a variety of models and parameter settings in our Picard scheme for
the two patients AAMH and AAAN to not only assess the performance of our method but also study its
sensitivity towards parameter changes and model complexity. We vary the reaction parameter ρ f between
0 and 15 and choose the diffusion coefficient k f either as 0 or 1.00E−2. See §5.1 for additional details on
the setup of the test case and the parameters.
Results. Fig. 5 – Fig. 7 show the healthy atlas (k = 1) in the top row and the corresponding patient
image with tumor in the bottom row for axial, saggital, and coronal orientations. The hard segmenta-
tions for the results computed with the proposed approach are shown in the middle row using the same
orientations. In Tab. 6, we summarize the results for all patient datasets. We report the initial and final
values for the mismatch and Dice coefficients associated with the probability maps for the tumor and the
brain anatomy, as well as the relative norm of the gradient of the coupled problem in (3). We also report
timings for the entire inversion. Fig. 8 shows more detailed images of the probability maps for the patient
AAMH (complex and large tumor). More detailed visual results with information on more iterations of
our inversion algorithm for all patients are given in §Appendix A (Fig. A.11 through Fig. A.16). Results
for varying reaction and diffusion for AAMH and AAAN are listed in Tab. 7. Note that all parameter
choices refer to the model used for tumor reconstruction in the Picard scheme. The true growth parame-
ters of the tumors are unknown.
Observations. The most important observation is that we obtain very good registration results—
qualitatively and quantitatively—in what is an extremely challenging registration problem. From visual
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Figure 5: Tumor and brain labels for the real tumor with real velocity (RTRV) test case; ground truth (ρ N/A, k N/A, p N/A, v N/A);
patients AAMH, AAAN. We set the parameters for the tumor solver to ρ f = 15, k f = 0 (reaction-only). We use np = 343 Gaussians for the
inversion. The top row shows the original atlas image. The bottom row shows the patient image. The row in the middle shows the solution for
our coupled scheme.
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Figure 6: Tumor and brain geometry for the real tumor with real velocity (RTRV) test case; ground truth (ρ N/A, k N/A, p N/A, v N/A);
patients AAAC, AAMP. We set the parameters for the tumor solver to ρ f = 15, k f = 0 (reaction-only). We use np = 343 Gaussians for the
inversion. The top row shows the original atlas image. The bottom row shows the patient image. The row in the middle shows the solution for
our coupled scheme.
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Figure 7: Tumor and brain geometry for the real tumor with real velocity (RTRV) test case; ground truth (ρ N/A, k N/A, p N/A, v N/A);
patients AAQD, AAWI. We set the parameters for the tumor solver to ρ f = 15, k f = 0 (reaction-only). We use np = 343 Gaussians for the
inversion. The top row shows the original atlas image. The bottom row shows the patient image. The row in the middle shows the solution for
our coupled scheme.
Table 6: Summary of results for the real tumor with real velocity (RTRV) test case, ground truth (ρ N/A, k N/A, p N/A, v N/A); based on
real clinical data (taken from (Gooya et al., 2013)). We set the tumor parameters to ρ f = 15, k f = 0 (reaction-only). We use a parametrization
of tumor initial conditions with np = 343 Gaussians. We report the (summed) mismatch for the brain tissue probability maps (µB,L2 ) and tumor
probability map (µT,L2 ) in patient space, the mean Dice coefficient for the hard segmentation corresponding to the brain tissue (DICEB) and the
tumor (DICET), respectively, as well as the relative norm of the gradient for the coupled problem (3) (‖g‖rel). We also report the total run time
in seconds (Ttotal), and the run time of the individual components of our Picard scheme, respectively (also in seconds; tumor solver: Ttuinv; image
registration: Treginv ). Note that the latter sums up to less than the reported total run time as we do not explicitly measure time spent in additional
coupling functionality and forward solvers. We execute our code in parallel on on 11 nodes using 256 MPI tasks of HazelHen.
Patient βv µB,L2 DICEB µT,L2 DICET ‖g‖rel Ttotal [s] Ttuinv [s] T
reg
inv [s]
AAMH initial 1 1.00 5.75E−1 1.00 0.00 1.00 – – –final 1E−4 3.45E−1 8.43E−1 1.95E−1 9.57E−1 3.92E−2 6.28E+2 1.95E+2 4.35E+2
AAAN initial 1 1.00 5.76E−1 1.00 0.00 1.00 – – –final 1E−4 3.54E−1 8.74E−1 3.77E−1 8.91E−1 1.06E−1 6.34E+2 2.15E+2 4.17E+2
AAAC initial 1 1.00 6.09E−1 1.00 0.00 1.00 – – –final 1E−4 3.36E−1 8.81E−1 2.45E−1 9.55E−1 4.38E−2 4.92E+2 1.59E+2 3.32E+2
AAMP initial 1 1.00 6.04E−1 1.00 0.00 1.00 – – –final 1E−4 3.32E−1 8.52E−1 1.34E−1 9.75E−1 3.31E−2 6.48E+2 2.36E+2 4.13E+2
AAQD initial 1.00 1.00 4.65E−1 1.00 0.00 1.00 – – –final 1E−4 3.24E−1 8.51E−1 2.55E−1 9.31E−1 9.88E−2 1.10E+3 2.19E+2 8.81E+2
AAWI initial 1 1.00 5.88E−1 1.00 0.00 1.00 – – –final 1E−4 3.45E−1 8.38E−1 3.92E−1 8.74E−1 5.26E−2 6.84E+2 2.92E+2 3.90E+2
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iterations βv µB,L2 DICEB µT,L2 DICET ‖g‖rel Tit [s] Ttuinv [%] T
reg
inv [%]
initial – 1.00 5.75E−1 1.00 0.00 1.00 – – –
1 1 9.59E−1 5.95E−1 1.00 0.00 9.99E−1 9.80E+1 74.6 15.0
2 1E−1 7.42E−1 6.68E−1 3.90E−1 8.43E−1 9.06E−2 4.55E+1 51.2 47.7
3 1E−2 5.05E−1 7.74E−1 3.13E−1 9.03E−1 4.61E−2 9.59E+1 25.8 73.7
4 1E−3 3.91E−1 8.23E−1 2.52E−1 9.39E−1 3.69E−2 1.18E+2 21.5 78.0
5 1E−4 3.60E−1 8.36E−1 2.20E−1 9.51E−1 3.62E−2 1.15E+2 21.2 78.3
6 1E−4 3.51E−1 8.40E−1 2.05E−1 9.55E−1 3.84E−2 8.99E+1 27.0 72.4
7 1E−4 3.45E−1 8.43E−1 1.95E−1 9.57E−1 3.92E−2 6.63E+1 – 99.3
final 1E−4 3.45E−1 8.43E−1 1.95E−1 9.57E−1 3.92E−2 6.28E+2 1.95E+2 4.35E+2
Figure 8: Results for the real tumor/ real velocity (RTRV) test case, ground truth (ρ N/A, k N/A, p N/A, v N/A) and the AAMH patient.
The figure shows probability maps for the labels of the healthy atlas brain (k = 1; top row) and the AAMH patient (target) brain probability
maps with tumor (bottom row), along with the reconstructed probability maps, i.e., the final result of our inversion algorithm (k = 7; middle
row) (axial-slice 120). In the table, we report the (summed) mismatch for the brain tissue probability maps (µB,L2 ) and tumor probability map
(µT,L2 ) in patient space, the mean Dice coefficient for the hard segmentation corresponding to the brain tissue (DICEB) and the tumor DICET ,
respectively, as well as the relative norm of the gradient for the coupled problem (3) (‖g‖rel). We also report the run time per iteration in seconds
(Tit), and the percentages (Ttuinv) and (T
reg
inv ) of this runtime spent in the tumor solver and the image registration solver, respectively. Note that
the latter sums up to less than 100% as we do not explicitly measure time spent in additional coupling functionality and in the forward solvers.
The last row shows the final state and summed absolute timings for the respective solvers in seconds.
inspection of the data alone (Fig. 5 through Fig. 7) we can immediately see that there are significant
anatomical differences between the atlas image and the patient images, and accross patients. The tumors
vary significantly in shape and size. Overall, this poses considerable challenges to our framework. The
results reported in Fig. 5 through Fig. 7 and in Fig. 8 clearly demonstrate that the deformed atlases are in
very good agreement with the patient data for all six subjects. We reach Dice coefficients between 8.38E−1
to 8.81E−1 and 8.74E−1 to 9.75E−1 for the probability maps associated with the anatomy and the tumor.
These results are slightly worse than those obtained for the artificially grown tumors in the former sec-
tions, but still competitive. We also note that the initial Dice coefficients for the anatomy range between
4.65E−1 and 6.04E−1 for these data, which is drastically worse than what we have seen in our synthetic
test cases. The runtimes are compareable to our former experiment. We again achieve a reduction of the
relative norm of the gradient for the coupled problem in (3) of about two orders of magnitude (slightly
less than what we saw before). The results of our study with varying tumor model parameters presented
in Tab. 7 show that there are slight variances in the results depending on the parameter choices, but the
Picard iteration scheme is successful in all cases. Further enhancements of our environment are required
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Table 7: Results for the AAMH and the AAAN patient real tumor/ real velocity (RTRV) test case, ground truth (ρ N/A, k N/A, p N/A, v
N/A) using real clinical input data. The table shows the (summed) mismatch for the brain tissue probability maps (µB,L2 ) and tumor probability
map (µT,L2 ) in patient space, the mean Dice coefficient for the hard segmentation corresponding to the brain tissue (DICEB) and the tumor
(DICET), respectively for different values for reaction scaling parameter ρ f and of the diffusion coefficient scaling parameter k f ., as well as the
relative norm of the gradient for the coupled problem (3) (‖g‖rel). We also report the total run time in seconds (Ttotal), and the run time of the
individual components of our Picard scheme, respectively (also in seconds; tumor solver: Ttuinv; image registration: T
reg
inv ). Note that the latter
sums up to less than the reported total run time as we do not explicitly measure time spent in additional coupling functionality and forward
solvers. We execute our code in parallel on on 11 nodes using 256 MPI tasks of HazelHen.
AAMH
ρ f k f np It βv µB,L2 DICEB µT,L2 DICET ‖g‖rel Ttotal [s] Ttuinv [s] Treginv [s]
0 0 343 initial 1 1.00 5.75E−1 1.00 0.00 1.00 – – –final 1E−4 3.40E−1 8.43E−1 1.47E−1 9.69E−1 1.19E−1 6.09E+2 2.13E+2 3.63E+2
0 0 125 initial 1 1.00 5.75E−1 1.00 0.00 1.00 – – –final 1E−4 3.38E−1 8.45E−1 1.73E−1 9.62E−1 1.31E−1 5.09E+2 7.86E+1 4.04E+2
15 0 343 initial 1 1.00 5.75E−1 1.00 0.00 1.00 – – –final 1E−4 3.45E−1 8.43E−1 1.95E−1 9.57E−1 3.92E−2 6.28E+2 1.95E+2 4.35E+2
15 0 125 initial 1 1.00 5.75E−1 1.00 0.00 1.00 – – –final 1E−4 3.50E−1 8.43E−1 2.36E−1 9.53E−1 4.83E−2 4.47E+2 7.20E+1 3.48E+2
5 1E−2 343 initial 1 1.00 5.75E−1 1.00 0.00 1.00 – – –final 1E−4 3.44E−1 8.43E−1 1.88E−1 9.64E−1 7.68E−2 1.23E+4 1.18E+4 3.41E+2
10 1E−2 343 initial 1 1.00 5.75E−1 1.00 0.00 1.00 – – –final 1E−4 3.46E−1 8.43E−1 2.07E−1 9.62E−1 5.16E−2 1.33E+4 1.28E+4 3.44E+2
15 1E−2 343 initial 1 1.00 5.75E−1 1.00 0.00 1.00 – – –final 1E−4 3.48E−1 8.44E−1 2.35E−1 9.59E−1 3.47E−2 1.18E+4 1.13E+4 3.63E+2
AAAN
ρ f k f np It βv µB,L2 DICEB µT,L2 DICET ‖g‖rel Ttotal [s] Ttuinv [s] Treginv [s]
0 0 343 initial 1 1.00 5.76E−1 1.00 0.00 1.00 – – –final 1E−4 3.42E−1 8.79E−1 2.56E−1 9.36E−1 2.19E−1 6.58E+2 2.02E+2 4.23E+2
0 0 125 initial 1 1.00 5.76E−1 1.00 0.00 1.00 – – –final 1E−4 3.56E−1 8.74E−1 4.40E−1 6.68E−1 2.36E−1 4.54E+2 8.89E+1 3.38E+2
15 0 343 initial 1 1.00 5.76E−1 1.00 0.00 1.00 – – –final 1E−4 3.54E−1 8.74E−1 3.77E−1 8.91E−1 1.06E−1 6.34E+2 2.15E+2 4.17E+2
15 0 125 initial 1 1.00 5.76E−1 1.00 0.00 1.00 – – –final 1E−4 3.67E−1 8.72E−1 5.71E−1 3.44E−1 1.28E−1 4.67E+2 8.38E+1 3.57E+2
5 1E−2 343 initial 1 1.00 5.76E−1 1.00 0.00 1.00 – – –final 1E−4 3.50E−1 8.76E−1 3.17E−1 9.06E−1 1.79E−1 1.82E+4 1.77E+4 3.33E+2
10 1E−2 343 initial 1 1.00 5.76E−1 1.00 0.00 1.00 – – –final 1E−4 3.52E−1 8.76E−1 3.60E−1 8.85E−1 1.41E−1 1.88E+4 1.82E+4 3.41E+2
15 1E−2 343 initial 1 1.00 5.76E−1 1.00 0.00 1.00 – – –final 1E−4 3.55E−1 8.75E−1 3.98E−1 8.62E−1 1.13E−1 1.85E+4 1.80E+4 3.28E+2
to enable the identification of the ’correct’ tumor growth parametrization.
Conclusions: We have tested our formulation on real data that pose significant challenges due to
large inter-subject anatomical variability and a strong variation in the appearance of the tumor, in shape,
size, location and growth behaviour. We use a very simple model that only accounts for logistic growth.
This, in combination with a flexible, high-dimensional parameterization of the initial condition allows
us to overcome these challenges. We achieve extremely promising registration accuracies with a Dice
score of up to 8.81E−1 and 9.75E−1 for the label maps associated with the probability maps of the brain
anatomy and the tumor in what is an extremely challenging problem. Runs with variation of the growth
parameter ρ f show, on the one hand, that it is important to identify the correct parameters to achieve
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optimal quality of tumor reconstruction. We, therefore, believe that it will be possible to identify physical
tumor growth parameters from our coupled solver if the tumor model is enhanced (anisotropic diffusion,
mass effect, . . . ) and we consider ’correct’ time horizons and/or restrict the initial conditions of tumor to
points seeds (see first steps following this idea in ATAV-LD). On the other hand, the results for varying
model parameters show the robustness of our Picard scheme with respect to the model and parameter
choice. Furthermore, the reconstruction results for the AAAN patient data show that we can reconstruct
multifocal tumors with comparable quality and computational costs.
6. Conclusion
We have presented a new method for the registration of images of patients diagnosed with mono- or
multi-focal brain tumors to a common reference atlas. Application scenarios are biophysical model cali-
bration and image registration. Our method combines stand-alone forward and inverse tumor (Gholami
et al., 2016b) and diffeomorphic registration (Mang and Biros, 2015, 2016; Mang et al., 2016; Mang and
Biros, 2017) by means of an efficient coupling scheme based on a Picard iteration. It allows us to ex-
ploit available, tailored implementations for the solution of the subproblems (Mang et al., 2016; Gholami
et al., 2017), while monitoring convergence using the coupled gradient information. We invert simultane-
ously for the control variables of both problems—a parameterization of the initial condition for the tumor
model, and a smooth velocity field to capture the inter-subject variability of brain anatomy. Here is what
we have learned from our experiments on synthetic and real data:
(i) Despite the fact that our scheme neglects coupling terms that appear in our coupled optimization
problem, we could experimentally show that it efficiently reduces the coupled gradient. A conver-
gence proof of the Picard scheme to a local minimum is beyond the scope of this paper and remains
subject to future work.
(ii) We could demonstrate that our parameterization of the initial condition allows us to generate high-
fidelity registrations irrespective of the complexity of the data or the model used for the tumor
simulations. If we reduce the number of basis functions used for initial condition parametrization,
this is no longer true.
(iii) In studies with various models from a pure interpolation with the basis functions that parameterize
the initial condition (zero reaction and diffusion coefficient) over a reaction-only, to a full reaction-
diffusion model, we could show in our synthetic cases, that we get the highest accuracy in tumor
reconstruction, if we use the correct model. This implies that our framework could eventually serve
as a powerful tool for model selection. A rigorous verification of this claim requires significantly
more work and remains for the future.
(iv) Overall, our numerical study, which includes real brain images with real tumors, shows that we
can achieve high-fidelity results with an overall low mismatch and high Dice score in particular for
the simulated and observed tumor, with Dice coefficients ranging from 93% for real tumors above a
critical size, and up to 97% for artificially grown tumors in a real brain geometry.
Let us emphasize that our tumor model is currently not sophisticated enough to allow proper parameter
identification or tumor growth prediction, but the tumor-registration coupling approach that we present
in this work and for which we can show good computational performance and high accuracy for vari-
ous real brain data test cases lays the basis for further developments with improved tumor solvers and,
finally, a parameter identification and growth prediction tool. The next steps for SIBIA are to improve
the biophysical tumor-growth model by first adding mass-effect and second higher-fidelity tumor growth
models.
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Appendix A. Supplementary Material
Appendix A.1. Supplementary Material for the ATAV Testcase
We present additional qualitative data for the ATAV-DIF testcase and the ATAV-LD testcase.
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Figure A.9: Tumor and brain labels (obtained by thresholding probability maps) for the analytic tumor with analythic velocity with non-
zero diffusion (ATAV-DIF) test case; ground truth: (ρ f = 10, ρw = 1, ρg = 0, k f = 1.00E−2, kw = 1, kg = 0, p = p?, v = −v?). We
show results for the inversion (velocity and initial condition) if we use the true (‘’correct‘’) tumor parameters used to generate the test case (i.e.,
ρ f = 10 and k f = 1.00E−2). The top row shows the initial label maps for the atlas image. The middle row shows the label maps for the atlas
image after registration (transported to the patient space) and the bottom row shows the label maps for the patient data. We can see that the results
are qualitatively in excellent agreement. This is confirmed by the values for the mismatch and Dice coefficients for the labels and probability maps
for the individual tissue classes reported in Tab. 4.
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Figure A.10: Tumor and brain labels for the analythic tumor with analythic velocity with non-zero diffusion and low-dimensional
initial condition (ATAV-LD) test case; ground truth: (ρ f = 15, ρw = 1, ρg = 0, k f = 1.00E−1, kw = 1, kg = 0, p = p? (in patient domain),
v N/A); for the ’correct’ tumor parameters ρ f = 15, k f = 1.00E−1, and the two different settings ρ f = 15, k f = 5.00E−1 and ρ f = k f = 0.
Appendix A.2. Supplementary Material for the RTRV Testcase
We show detailed results for the RTRV real data test cases for six patient datasets (AAAC, AAAN,
AAMP, AAMH, AAQD, AAWI; first proposal for a patient segmentation produced in the first iteration of
GLISTR (Gooya et al., 2013)). Fig. A.11 through Fig. A.16 show axial slices of the evolution of the proba-
bility maps of the atlas brain tissue labels (in patient space) and the reconstructed tumor (in patient space)
throughout our inversion algorithm. Brain tissue probability maps, tumor probability map, mismatch for
all labels as well as the hard segmentation image are given for Picard iterations k = {1, 2, 4, 6}.
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Figure A.11: Results for the real tumor/ real velocity (RTRV) test case, ground truth (ρ N/A, k N/A, p N/A, v N/A) and the AAAC patient.
The figure shows probability maps for the labels of the healthy atlas brain (k = 1; top row) and the AAAN patient (target) brain probability maps
with tumor (bottom row), along with the reconstructed probability maps throughout the Picard iterations (k = 2, 4, 6) (axial-slice 132).
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Figure A.12: Results for the real tumor/ real velocity (RTRV) test case, ground truth (ρ N/A, k N/A, p N/A, v N/A) and the AAAN patient.
The figure shows probability maps for the labels of the healthy atlas brain (k = 1; top row) and the AAAN patient (target) brain probability maps
with tumor (bottom row), along with the reconstructed probability maps throughout the Picard iterations (k = 2, 4, 6) (axial-slice 132).
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Figure A.13: Results for the real tumor/ real velocity (RTRV) test case, ground truth (ρ N/A, k N/A, p N/A, v N/A) and the AAMP patient.
The figure shows probability maps for the labels of the healthy atlas brain (k = 1; top row) and the AAAN patient (target) brain probability maps
with tumor (bottom row), along with the reconstructed probability maps throughout the Picard iterations (k = 2, 4, 6) (axial-slice 132).
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Figure A.14: Results for the real tumor/ real velocity (RTRV) test case, ground truth (ρ N/A, k N/A, p N/A, v N/A) and the AAMH patient.
The figure shows probability maps for the labels of the healthy atlas brain (k = 1; top row) and the AAAN patient (target) brain probability maps
with tumor (bottom row), along with the reconstructed probability maps throughout the Picard iterations (k = 2, 4, 6) (axial-slice 120).
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Figure A.15: Results for the real tumor/ real velocity (RTRV) test case, ground truth (ρ N/A, k N/A, p N/A, v N/A) and the AAQD patient.
The figure shows probability maps for the labels of the healthy atlas brain (k = 1; top row) and the AAAN patient (target) brain probability maps
with tumor (bottom row), along with the reconstructed probability maps throughout the Picard iterations (k = 2, 4, 6) (axial-slice 136).
37
0 0.2 0.4 0.6 0.8 1
WM
k
=
1
0 0.2 0.4 0.6 0.8 1
Atlas Configuration in Patient Space
GM
0 0.2 0.4 0.6 0.8 1
CSF
0 0.2 0.4 0.6 0.8 1
TU
0 0.2 0.4 0.6 0.8 1
WM
0 0.2 0.4 0.6 0.8 1
Residual
GM
0 0.2 0.4 0.6 0.8 1
CSF
0 0.2 0.4 0.6 0.8 1
TU
Thresholded Maps
0 0.2 0.4 0.6 0.8 1
k
=
2
0 0.2 0.4 0.6 0.8 10 0.2 0.4 0.6 0.8 10 0.2 0.4 0.6 0.8 10 0.2 0.4 0.6 0.8 10 0.2 0.4 0.6 0.8 10 0.2 0.4 0.6 0.8 10 0.2 0.4 0.6 0.8 1
0 0.2 0.4 0.6 0.8 1
k
=
4
0 0.2 0.4 0.6 0.8 10 0.2 0.4 0.6 0.8 10 0.2 0.4 0.6 0.8 10 0.2 0.4 0.6 0.8 10 0.2 0.4 0.6 0.8 10 0.2 0.4 0.6 0.8 10 0.2 0.4 0.6 0.8 1
0 0.2 0.4 0.6 0.8 1
k
=
6
0 0.2 0.4 0.6 0.8 10 0.2 0.4 0.6 0.8 10 0.2 0.4 0.6 0.8 10 0.2 0.4 0.6 0.8 10 0.2 0.4 0.6 0.8 10 0.2 0.4 0.6 0.8 10 0.2 0.4 0.6 0.8 1
0 0.2 0.4 0.6 0.8 1
WM
0 0.2 0.4 0.6 0.8 1
Patient Configuration
GM
0 0.2 0.4 0.6 0.8 1
CSF
0 0.2 0.4 0.6 0.8 1
TU
Thresholded Maps
Figure A.16: Results for the real tumor/ real velocity (RTRV) test case, ground truth (ρ N/A, k N/A, p N/A, v N/A) and the AAWI patient.
The figure shows probability maps for the labels of the healthy atlas brain (k = 1; top row) and the AAAN patient (target) brain probability maps
with tumor (bottom row), along with the reconstructed probability maps throughout the Picard iterations (k = 2, 4, 6) (axial-slice 132).
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